1 min read
Add as a preferred source on GoogleVeracyte Shares Fall 56% After Updating 2026 Revenue Outlook
The stock fell $29.18 to $23.34 in the final half-hour of Thursday’s trading.
Veracyte shares fell 56% Thursday, Nov. 5, after the cancer-focused molecular diagnostics company released third-quarter results and updated its 2026 revenue outlook, with shares sliding $29.18 late in the session.
The stock reached $23.34 during the final half-hour of trading. Veracyte is a global molecular diagnostics company focused on cancer care, and its shares trade on Nasdaq under the ticker VCYT.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.